Journal Mobile Options
Table of Contents
Vol. 118, No. 2-4, 2007
Issue release date: November 2007
Cytogenet Genome Res 118:337–344 (2007)

Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive and negative subsets and histologic progression

Nanjangud G. · Rao P.H. · Teruya-Feldstein J. · Donnelly G. · Qin J. · Mehra S. · Jhanwar S.C. · Zelenetz A.D. · Chaganti R.S.K.
aCell Biology Program, and the Departments of bPathology, cMedicine, and dEpidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY; eDepartment of Pediatrics, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, TX (USA)

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


We analyzed a cohort of 61 follicular lymphomas (FL) with an abnormal G-banded karyotype by spectral karyotyping (SKY) to better define the chromosome instability associated with the t(14;18)(q32;q21) positive and negative subsets of FL and histologic grade. In more than 70% of the patients, SKY provided additional cytogenetic information and up to 40% of the structural abnormalities were revised. The six most frequent breakpoints in both SKY and G-banding analyses were 14q32, 18q21, 3q27, 1q11–q21, 6q11–q15 and 1p36 (15–77%). SKY detected nine additional sites (1p11–p13, 2p11–p13, 6q21, 8q24, 6q21, 9p13, 10q22–q24, 12q11–q13 and 17q11–q21) at an incidence of >10%. In addition to the known recurring translocations, t(14;18)(q32;q21) [70%], t(3;14)(q27;q32) [10%], t(1;14)(q21;q32) [5%] and t(8;14)(q24;q32) [2%] and their variants, 125 non-IG gene translocations were identified of which four were recurrent within this series. In contrast to G-banding analysis, SKY revealed a greater degree of karyotypic instability in the t(14;18) (q32;q21) negative subset compared to the t(14;18)(q32;q21) positive subset. Translocations of 3q27 and gains of chromosome 1 were significantly more frequent in the former subset. SKY also allowed a better definition of chromosomal imbalances, thus 37% of the deletions detected by G-banding were shown to be unbalanced translocations leading to gain of genetic material. The majority of recurring (>10%) imbalances were detected at a greater (2–3 fold) incidence by SKY and several regions were narrowed down, notably at gain 2p13–p21, 2q11–q21, 2q31–q37, 12q12–q15, 17q21–q25 and 18q21. Chromosomal abnormalities among the different histologic grades were consistent with an evolution from low to high grade disease and breaks at 6q11–q15 and 8q24 and gain of 7/7q and 8/8q associated significantly with histologic progression. This study also indicates that in addition to gains and losses, non-IG gene translocations involving 1p11–p13, 1p36, 1q11–q21, 8q24, 9p13, and 17q11–q21 play an important role in the histologic progression of FL with t(14;18)(q32;q21) and t(3q27).

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Anderson JR, Armitage JO, Weisenburger DD: Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations: Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 9:717–720 (1998).
  2. Armitage JO, Sanger WG, Weisenburger DD, Harrington DS, Linder J, et al: Correlation of secondary cytogenetic abnormalities with histologic appearance in non-Hodgkin’s lymphomas bearing t(14;18)(q32;q21): J Natl Cancer Inst 80:576–580 (1988).
  3. Avet-Loiseau H, Vigier M, Moreau A, Mellerin MP, Gaillard F, et al: Comparative genomic hybridization detects genomic abnormalities in 80% of follicular lymphomas. Br J Haematol97:119–122 (1997).
  4. Bentz M, Werner CA, Dohner H, Joos S, Barth TF, et al: High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma. Blood88:1437–1444 (1996).
  5. Callanan MB, Le Baccon P, Mossuz P, Duley S, Bastard C, et al: The IgG Fc receptor, FcgammaRIIB, is a target for deregulation by chromosomal translocation in malignant lymphoma. Proc Natl Acad Sci USA 97:309–314 (2000).
  6. Chen W, Palanisamy N, Schmidt H, Teruya-Feldstein J, Jhanwar SC, et al: Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. Oncogene 20:7686–7693 (2001).
  7. Cigudosa JC, Parsa NZ, Louie DC, Filippa DA, Jhanwar SC, et al: Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes Chromosomes Cancer 25:123–133 (1999).
  8. Dave BJ, Pickering DL, Hess MM, Weisenburger DD, Armitage JO, Sanger WG: Deletion of cell division cycle 2-like 1 gene locus on 1p36 in non- Hodgkin lymphoma. Cancer Genet Cytogenet 108:120–126 (1999).
  9. Dyomin VG, Palanisamy N, Lloyd KO, Dyomina K, Jhanwar SC, et al: MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 95:2666–2671 (2000).
  10. Hedvat CV, Hegde A, Chaganti RS, Chen B, Qin J, et al: Application of tissue microarray technology to the study of non-Hodgkin’s and Hodgkin’s lymphoma. Hum Pathol 33:968–974 (2002).
  11. Horsman DE, Connors JM, Pantzar T, Gascoyne RD : Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). Genes Chromosomes Cancer 30:375–382 (2001).
  12. Horsman DE, Okamoto I, Ludkovski O, Le N, Harder L, et al: Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. Br J Haematol 120:424–433 (2003).
  13. ISCN 1995: An International System for Human Cytogenetic Nomenclature, Mitelman F (ed) (S. Karger, Basel 1995).
  14. Juneja S, Matthews J, Lukeis R, Laidlaw C, Cooper I, et al: Prognostic value of cytogenetic abnormalities in previously untreated patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 25:493–501 (1997).
  15. Knutsen T: Cytogenetic mechanisms in the pathogenesis and progression of follicular lymphoma. Cancer Surv 30:163–192 (1997).
  16. Lestou VS, Gascoyne RD, Sehn L, Ludkovski O, Chhanabhai M, et al: Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. Br J Haematol 122:745–759 (2003).
  17. Lossos IS, Levy R: Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol 13:191–202 (2003).
  18. Martinez-Climent JA, Alizadeh AA, Segraves R, Blesa D, Rubio-Moscardo F, et al: Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 101:3109–3117 (2003).
  19. McDonnell TJ, Korsmeyer SJ: Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 349:254–256 (1991).
  20. Nanjangud G, Rao PH, Hegde A, Teruya-Feldstein J, Donnelly G, et al: Spectral karyotyping identifies new rearrangements, translocations, and clinical associations in diffuse large B-cell lymphoma. Blood 99:2554–2561 (2002).
  21. Nathwani BHN, Weisenberger D: Follicular lymphoma, in: Jaffe EHN, Stien H, Vardiman J (eds): Pathology and Genetics of Tumours of Haematopoetic and Lymphoid tissues, pp 162–167 (IARC press, Lyon, 2001).
  22. Offit K, Jhanwar SC, Ladanyi M, Filippa DA, Chaganti RS: Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin’s lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment. Genes Chromosomes Cancer 3:189–201 (1991).
  23. Rao PH, Murty VV, Gaidano G, Hauptschein R, Dalla-Favera R, Chaganti RS: Subregional localization of 20 single-copy loci to chromosome 6 by fluorescence in situ hybridization. Genomics 16:426–30 (1993).
  24. Rao PH, Cigudosa JC, Ning Y, Calasanz MJ, Iida S, et al: Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood92:1743–1748 (1998).
  25. Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, et al: Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 92:4269–4278 (1998).
  26. Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, et al: Multicolor spectral karyotyping of human chromosomes. Science273:494–497 (1996).
  27. Tilly H, Rossi A, Stamatoullas A, Lenormand B, Bigorgne C, et al: Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood 84:1043–1049 (1994).
  28. Tsujimoto Y, Ikegaki N, Croce CM: Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene 2:3–7 (1987).
  29. Viardot A, Barth TF, Moller P, Dohner H, Bentz M: Cytogenetic evolution of follicular lymphoma. Semin Cancer Biol 13:183–90 (2003).
  30. Whang-Peng J, Knutsen T, Jaffe ES, Steinberg SM, Raffeld M, et al: Sequential analysis of 43 patients with non-Hodgkin’s lymphoma: clinical correlations with cytogenetic, histologic, immunophenotyping, and molecular studies. Blood 85:203–216 (1995).
  31. Yunis JJ, Frizzera G, Oken MM, McKenna J, Theologides A, Arnesen M: Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N Engl J Med 316:79–84 (1987).

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50